References
1. Jacobs S.E., Lamson D.M., Kirsten S., Walsh T.J. Human rhinoviruses. Clin Microbiol Rev. 2013; 26 (1): 135–62. DOI: https://doi.org/10.1128/CMR.00077-12
2. To K.W, Yip C.Y, Yuen K.Y. Rhinovirus – From bench to bedside. J Formos Med Assoc. 2017; 116 (7): 496–504. DOI: https://doi.org/10.1016/J.JFMA.2017.04.009
3. Rollinger J.M., Schmidtke M. The human rhinovirus: human-pathological impact, mechanisms of antirhinoviral agents, and strategies for their discovery. Med Res Rev. 2011; 31 (1): 42–92. DOI: https://doi.org/10.1002/MED.20176
4. Hayashi Y., Sada M., Shirai T., Okayama K., Kimura R., Kondo M., Okodo M., Tsugawa T., Ryo A., Kimura H. Rhinovirus Infection and Virus-Induced Asthma. Viruses. 2022; 14 (12): 2616. DOI: https://doi.org/10.3390/V14122616
5. Lee J.S., Kim S.R., Song J.H., Lee Y.P., Ko H.J. Anti-Human Rhinovirus 1B Activity of Dexamethasone viaGCR-Dependent Autophagy Activation. Osong Public Health Res Perspect. 2018; 9 (6): 334–9. DOI: https://doi.org/10.24171/J.PHRP.2018.9.6.07
6. Jackson D.J., Gern J.E. Rhinovirus Infections and Their Roles in Asthma: Etiology and Exacerbations. J Allergy Clin Immunol Pract. 2022; 10 (3): 673–81. DOI: https://doi.org/10.1016/J.JAIP.2022.01.006
7. Gunawardana N., Finney L., Johnston S.L., Mallia P. Experimental rhinovirus infection in COPD: implications for antiviral therapies. Antiviral Res. 2014; 102: 95–105. DOI: https://doi.org/10.1016/J.ANTIVIRAL.2013.12.006
8. Price A.S., Kennedy J.L. T-helper 2 mechanisms involved in human rhinovirus infections and asthma. Ann Allergy Asthma Immunol. 2022; 129 (6): 681–91. DOI: https://doi.org/10.1016/J.ANAI.2022.08.015
9. Casanova V., Sousa F.H., Stevens C., Barlow P.G. Antiviral therapeutic approaches for human rhinovirus infections. Future Virol. 2018; 13 (7): 505–18. DOI: https://doi.org/10.2217/FVL-2018-0016
10. Ruuskanen O., Waris M., Ramilo O. New aspects on human rhinovirus infections. Pediatr Infect Dis J. 2013; 32 (5): 553–5. DOI: https://doi.org/10.1097/INF.0B013E3182833C90
11. Coultas J.A., Cafferkey J., Mallia P., Johnston S.L. Experimental Antiviral Therapeutic Studies for Human Rhinovirus Infections. J Exp Pharmacol. 2021; 13: 645–59. DOI: https://doi.org/10.2147/JEP.S255211
12. Shilovskiy I.P., Yumashev K. V., Nikolsky A.A., Vishnyakova L.I., Khaitov M.R. Molecular and Cellular Mechanisms of Respiratory Syncytial Viral Infection: Using Murine Models to Understand Human Pathology. Biochemistry (Moscow). 2021; 86 (3): 290–306. DOI: https://doi.org/10.1134/S0006297921030068
13. Khaitov M.R., Litvin L.S., Shilovsky I.P., Bashkatova Y.N., Faizuloev E.B., Zverev V.V. RNA interference. New approaches to the development of antiviral agents. Immunologiya. 2010; 31: 69–76.
14. Whangbo J.S., Hunter C.P. Environmental RNA interference. Trends Genet. 2008; 24 (6): 297–305. DOI: https://doi.org/10.1016/J.TIG.2008.03.007
15. Khaitov M., Nikonova A., Shilovskiy I., Kozhikhova K., Kofiadi I., Vishnyakova L., Nikolsky A., Gattinger P., Kovchina V., Barvinskaya E., Yumashev K., Smirnov V., Maerle A., Kozlov I., Shatilov A., Timofeeva A., Andreev S., Koloskova O., Kuznetsova N., Vasina D., Nikiforova M., Rybalkin S., Sergeev I., Trofimov D., Martynov A., Berzin I., Gushchin V., Kovalchuk A., Borisevich S., Valenta R., Khaitov R., Skvortsova V. Silencing of SARS-CoV-2 with modified siRNA-peptide dendrimer formulation. Allergy. 2021; 76 (9): 2840–54. DOI: https://doi.org/10.1111/all.14850
16. Khaitov M.R., Nikonova A.A., Shilovsky I.P., Kozhikhova K.V., Kofiadi I.A., Gudima G.O., Vishnyakova L.I., Nikolsky A.A., Kovchina V.I., Timotievich E.D., Yumashev K.V., Smirnov V.V., Maerle A.V., Kozlov I.B., Shatilov A.A., Shatilova A.V., Andreev S.M., Koloskova O.O., Kuznetsova N.A., Vasina D.V., Nikiforova M.A., Rybalkin S.P., Sergeev I.V., Trofimov D.Yu., Martynov A.I., Berzin I.A., Gushchin V.A., Kovalchuk A.V., Borisevich S.V., Skvortsova V.I. MIR 19® is the world’s first specific antiviral drug for the treatment of COVID-19: development and preclinical studies. Immunologiya. 2023; 44 (3): 270–90. DOI: https://doi.org/10.33029/0206-4952-2023-44-3-270-290 (in Russian)
17. Khaitov M.R., Nikonova A.A., Kofiadi I.A., Shilovsky I.P., Smirnov V.V., Elisyutina O.G., Gudima G.O., Maerle A.V., Shatilov A.A., Shatilova A.V., Andreev S.M., Sergeev I.V., Trofimov D.Yu., Latysheva T.V., Ilyina N.I., Martynov A.I., Rabdano S.O., Ruzanova E.A., Savelyev N.S., Pletyukhina Yu.V. Safi A.S., Ratnikov V.A., Gorelov V.P., Kashchenko V.A., Kucherenko N.G., Umarova I.A., Moskaleva S.S., Fabrichnikov S.V., Zuev O .V., Pavlov N.B., Kryuchko D.S., Berzin I.A., Goryachev D.V., Merkulov V.A., Shipulin G.A., Yudin S.M., Trukhin V.P., Valenta R., Skvortsova V.I. Results of phase I and II clinical trials of the drug MIR 19®. Immunologiya. 2023; 44 (3): 291–316. DOI: https://doi.org/10.33029/1816-2134-2023-44-3-291-316 (in Russian)
18. Harborth J., Elbashir S.M., Bechert K., Tuschl T., Weber K. Identification of essential genes in cultured mammalian cells using small interfering RNAs. J Cell Sci. 2001; 114 (24): 4557–65. DOI: https://doi.org/10.1242/JCS.114.24.4557
19. Ui-Tei K., Naito Y., Takahashi F., Haraguchi T., Ohki-Hamazaki H., Juni A., Ueda R., Saigo K. Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res. 2004; 3 2 (3): 936–48. DOI: https://doi.org/10.1093/nar/gkh247
20. Reynolds A., Leake D., Boese Q., Scaringe S., Marshall W.S., Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol. 2004; 22 (3): 326–30. DOI: https://doi.org/10.1038/nbt936
21. Gatta A.K., Hariharapura R.C., Udupa N., Reddy M.S., Josyula V.R. Strategies for improving the specificity of siRNAs for enhanced therapeutic potential. Expert Opinion on Drug Discovery. 2018; 13 (8): 709–25. DOI: https://doi.org/10.1080/17460441.2018.1480607
22. Koloskova O.O., Nosova A.S., Ilyukhina A.A., Shilovsky I.P., Sebyakin Yu.L., Khaitov M.R. Liposomal delivery vehicles for siRNA (review). Biopharmaceutical Journal. 2017; 9 (5). (in Russian)
23. Shilovsky I.P., Yumashev K.V., Kozhikhova K.V., Vishnyakova L.I., Smirnov V.V., Gudima G.O., Brylina V.E., Kaganova M.M., Nikolsky A. A.A., Timotievich E.D., Kovchina V.I., Rusak T.E., Shatilova A.V., Shatilov A.A., Andreev S.M., Kudlay D.A., Khaitov M.R. A synthetic peptide that mimics the antigenic site of the F protein suppresses respiratory syncytial virus infection in in vitro experiments. Immunologiya. 2023; 44 (2): 134–46. DOI: https://doi.org/10.33029/0206-4952-2023-44-2-134-146 (in Russian)
24. Shilovskiy I.P., Andreev S.M., Kozhikhova K.V., Nikolskii A.A., Khaitov MR. Prospects For the Use of Peptides against Respiratory Syncytial Virus. Mol Biol. 2019; 53 (4): 484–500. DOI: https://doi.org/10.1134/S0026893319040125/FIGURES/3
25. Vandini S., Biagi C., Fischer M., Lanari M. Impact of Rhinovirus Infections in Children. Viruses. 2019; 11 (6). DOI: https://doi.org/10.3390/V11060521
26. Casanova V., Sousa F.H., Stevens C., Barlow P.G. Antiviral therapeutic approaches for human rhinovirus infections. Future Virol. 2018; 13 (7): 505–18. DOI: https://doi.org/10.2217/FVL-2018-0016
27. Smee D.F., Evans W.J., Nicolaou K.C., Tarbet E.B., Day C.W. Susceptibilities of enterovirus D68, enterovirus 71, and rhinovirus 87 strains to various antiviral compounds. Antiviral Res. 2016; 131: 61–5. DOI: https://doi.org/10.1016/J.ANTIVIRAL.2016.04.003
28. Phipps K.M., Martinez A., Lu J., Heinz B.A., Zhao G. Small interfering RNA molecules as potential anti-human rhinovirus agents: In vitro potency, specificity, and mechanism. Antiviral Res. 2004; 61 (1): 49–55. DOI: https://doi.org/10.1016/j.antiviral.2003.08.005
29. Bochkov Y.A., Palmenberg A.C., Lee W.M., Rathe J.A., Amineva S.P., Sun X., Pasic T., Jarjour N., Liggett S., Gern J. Molecular modeling, organ culture and reverse genetics for a newly identified human rhinovirus C. Nature Medicine. 2011; 17 (5): 627–32. DOI: https://doi.org/10.1038/nm.2358